Localization of Mullerian inhibiting substance receptors in various human cancer cell lines

被引:0
|
作者
A. V. Rodina
N. V. Gukasova
V. A. Makarov
I. G. Kondrasheva
A. V. Khomyakova
G. A. Posypanova
O. N. Popova
E. Yu. Moskaleva
S. E. Severin
机构
[1] Moscow Research Institute of Medical Ecology,Moscow Department of Health Care
来源
Biochemistry (Moscow) | 2008年 / 73卷
关键词
human recombinant MIS; receptor localization; biological activity;
D O I
暂无
中图分类号
学科分类号
摘要
Recombinant human MIS (rhMIS) produced in transfected Chinese hamster ovary cells has been purified by immunoaffinity chromatography. In the absence of reducing agents, 140 kD homodimer and several oligomers with molecular masses from 280 to 1000 kD are present. Homodimer, tetramer, and higher-molecular-weight rhMIS fractions reduced survival of tumor cells. For these experiments, FITC-labeled rhMIS was used for binding and endocytosis studies by flow cytometry. Flow cytometry performed on MIS-sensitive cancer cell lines demonstrated specific binding of rhMIS. The majority of rhMIS receptors have cytosolic localization. Thus, the level of MIS receptors on the cell membrane was pro-portional to the content of MIS-binding proteins in the whole cell and defines a level of receptor-mediated endocytosis. The immunopurified rhMIS caused significant growth inhibition of ovarian and prostate adenocarcinoma and melanoma human cell lines in inhibition assays.
引用
收藏
相关论文
共 50 条
  • [41] The Human Theca Cells expressed Mullerian Inhibiting Substance/Anti-Mullerian Hormone Type II Receptor
    Kim, Jang Heub
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2019, 26 (12): : 1468 - 1468
  • [42] Mullerian inhibiting substance inhibits breast cancer cell growth through an NFκB-mediated pathway
    Segev, DL
    Ha, TU
    Tran, TT
    Kenneally, M
    Harkin, P
    Jung, M
    MacLaughlin, DT
    Donahoe, PK
    Maheswaran, S
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (37) : 28371 - 28379
  • [43] Mullerian Inhibiting Substance/anti-Mullerian hormone: a potential therapeutic agent for human ovarian and other cancers
    MacLaughlin, David T.
    Donahoe, Patricia K.
    FUTURE ONCOLOGY, 2010, 6 (03) : 391 - 405
  • [44] The regulation of adiponectin receptors in human prostate cancer cell lines
    Mistry, T.
    Digby, J. E.
    Chen, J.
    Desai, K. M.
    Randeva, H. S.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 348 (03) : 832 - 838
  • [45] THE INDUCTION OF CYTOTOXICITY BY PTEROSTILBENE IN VARIOUS HUMAN CANCER CELL LINES
    Wawszczyk, Joanna
    Jesse, Katarzyna
    Szewerniak, Aleksandra
    Kapral, Malgorzata
    Weglarz, Ludmila
    ACTA POLONIAE PHARMACEUTICA, 2018, 75 (05): : 1161 - 1166
  • [46] AN IMMUNOASSAY TO DETECT HUMAN MULLERIAN INHIBITING SUBSTANCE IN MALES AND FEMALES DURING NORMAL DEVELOPMENT
    HUDSON, PL
    DOUGAS, I
    DONAHOE, PK
    CATE, RL
    EPSTEIN, J
    PEPINSKY, RB
    MACLAUGHLIN, DT
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (01): : 16 - 22
  • [47] Evidence for a Mullerian-inhibiting substance autocrine/paracrine system in adult human endometrium
    Wang, Jeff
    Dicken, Cary
    Lustbader, Joyce W.
    Tortoriello, Drew V.
    FERTILITY AND STERILITY, 2009, 91 (04) : 1195 - 1203
  • [48] EFFECT OF HUMAN RECOMBINANT MULLERIAN INHIBITING SUBSTANCE ON ISOLATED EPITHELIAL AND MESENCHYMAL CELLS DURING MULLERIAN DUCT REGRESSION IN THE RAT
    TSUJI, M
    SHIMA, H
    YONEMURA, CY
    BRODY, J
    DONAHOE, PK
    CUNHA, GR
    ENDOCRINOLOGY, 1992, 131 (03) : 1481 - 1488
  • [49] An update on Mullerian-inhibiting substance: its potential application against ovarian cancer
    Wong, Raymond R. Y.
    Worley, Michael J., Jr.
    Chung, Tony K. H.
    Wong, Yick Fu
    ENDOCRINE-RELATED CANCER, 2014, 21 (03) : R227 - R233
  • [50] Mullerian inhibiting substance induces NFκB signaling in breast and prostate cancer cells
    Hoshiya, Y
    Gupta, V
    Segev, DL
    Hoshiya, M
    Carey, JL
    Sasur, LM
    Tran, TT
    Ha, TU
    Maheswaran, S
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2003, 211 (1-2) : 43 - 49